CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Fluvoxamine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02853136
NCT02853136Phase 1Completed
CompareCT.gov

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 After Oral Administration (Randomized, Open-label, Two-treatment, Two-sequence, Two-period Crossover Study)

Boehringer Ingelheim·interventional·Posted Aug 2, 2016·Updated Aug 21, 2024

In Brief

A Phase 1 clinical trial evaluating Fluvoxamine, BI 409306 - Powder for oral solution (PfOS), and 1 other intervention for Healthy. Completed, enrolled 18 participants across 1 site.

Detailed Summary

To investigate the influence of fluvoxamine on the pharmacokinetics of BI 409306

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2, 2016
Enrollment StartAug 25, 2016
Primary CompletionOct 17, 2016
Study CompletionOct 25, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.9 years ago

Interventions

Fluvoxaminedrug

Fluvoxamine

BI 409306 - Powder for oral solution (PfOS)drug

BI 409306 - Powder for oral solution (PfOS)

BI 409306 - film coated tabletdrug

BI 409306 - film coated tablet